New combo therapy aims to outsmart returning hodgkin lymphoma
Disease control
Not yet recruiting
This study tests a combination of the immunotherapy drug pembrolizumab and chemotherapy (GVD) in 38 adults whose Hodgkin lymphoma has returned or not responded to one prior treatment. The goal is to see if this approach can make the cancer disappear completely, using a sensitive …
Phase: PHASE2 • Sponsor: Michael Spinner, MD • Aim: Disease control
Last updated May 01, 2026 16:01 UTC